Senior Director, Roivant Sciences
Sara Núñez-García joined Roivant Sciences in 2019 as Senior Director; she is part of the investments team at Roivant Pharma.
Before Roivant, Sara served as a Principal with Sofinnova Partners, focusing on investments in the biopharmaceutical sector. Sara was involved in various investments such as Delinia Bio (sold to Celgene), ProQR Therapeutics (PRQR), Auris Medical (EARS), MedDay Pharma, ObsEva (OBSV), Enyo Pharma, Asceneuron, MyTomorrows, Leucid Bio and Comet Therapeutics. She was board director in Delinia Bio, Enyo Pharma and Comet Therapeutics. In addition, she served as an expert reviewer for the NIH.
Prior to joining Sofinnova Partners in 2013, Sara was an associate in the Licensing and M&A team at Onyx Pharmaceuticals (now Amgen) in California, where she proposed option-based and structured deals for various potential acquisitions in the oncology space.
Sara spent six years in the pharmaceutical industry with Solvay and Abbott Laboratories in The Netherlands as a preclinical development scientist. During her time at Abbott, Sara worked on multiple programmes for CNS indications, contributing to the submission of several IND packages. Three of those INDs are currently in clinical development.
Sara did her postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed several transition state inhibitors for oncology targets, one of which is currently in clinical development. Sara received her PhD in Chemistry from the University of Manchester, UK. Sara has published eighteen peer-reviewed articles and patents. In addition, Sara also holds an MBA from INSEAD with a major in Finance.